Mesalazine for the treatment of IBS-D

• Research type

  Research Study

• Full title

  Efficacy and mode of action of mesalazine in the treatment of diarrhoea-predominant irritable bowel syndrome (IBS-D).

• IRAS ID

  45376

• Contact name

  Robin Spiller

• Sponsor organisation

  University of Nottingham

• Eudract number

  2010-018340-14

• ISRCTN Number

  76612274

• Research summary

  Irritable bowel syndrome (IBS) is a common condition affecting 1 in 10 of the population. About a third of these suffer from diarrhoea, which severely impairs their quality of life. Recent evidence suggests this might be due to increases in mast cells and inflammation in the intestine. This may cause the intestine to become hypersensitive and thus cause abdominal pain. Mesalazine is an inexpensive safe drug widely used to treat bowel inflammation. In this study we want to find out if mesalazine results in a reduction in average stool frequency in people with IBS-D. This would indicate that mesalazine can help reduce inflammation, thus reducing abdominal pain and diarrhoea.

• REC name

  South Central - Oxford B Research Ethics Committee

• REC reference

  10/H0605/65

• Date of REC Opinion

  25 Nov 2010

• REC opinion

  Further Information Favourable Opinion